{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T22:14:51Z","timestamp":1772835291603,"version":"3.50.1"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T00:00:00Z","timestamp":1595980800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Clinical trials of typhoid conjugate vaccine (TCV) are ongoing in 4 countries. Early data confirm safety, tolerability, and immunogenicity of typhoid conjugate vaccine, and early efficacy results are promising. These data support World Health Organization recommendations and planned country introductions. Forthcoming trial data will continue to inform programmatic use of typhoid conjugate vaccine.<\/jats:p>","DOI":"10.1093\/cid\/ciaa370","type":"journal-article","created":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T19:11:15Z","timestamp":1585768275000},"page":"S155-S159","source":"Crossref","is-referenced-by-count":8,"title":["Early Insights From Clinical Trials of Typhoid Conjugate Vaccine"],"prefix":"10.1093","volume":"71","author":[{"given":"Kathleen M","family":"Neuzil","sequence":"first","affiliation":[{"name":"University of Maryland School of Medicine, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Buddha","family":"Basnyat","sequence":"additional","affiliation":[{"name":"Oxford University Clinical Research Unit, Patan Academy of Health Sciences, Kathmandu, Nepal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D","family":"Clemens","sequence":"additional","affiliation":[{"name":"Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melita A","family":"Gordon","sequence":"additional","affiliation":[{"name":"Malawi-Liverpool Wellcome Trust Clinical Research Programme, Blantyre, Malawi"},{"name":"Institute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyanka D","family":"Patel","sequence":"additional","affiliation":[{"name":"Malawi-Liverpool Wellcome Trust Clinical Research Programme, Blantyre, Malawi"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J","family":"Pollard","sequence":"additional","affiliation":[{"name":"Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom"},{"name":"National Institute for Health Research Oxford Biomedical Research Centre, Oxford, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mila","family":"Shakya","sequence":"additional","affiliation":[{"name":"Oxford University Clinical Research Unit, Patan Academy of Health Sciences, Kathmandu, Nepal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Firdausi","family":"Qadri","sequence":"additional","affiliation":[{"name":"Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,7,29]]},"reference":[{"key":"2020073002271401600_CIT0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1353\/dem.2005.0002","article-title":"The role of public health improvements in health advances: the twentieth-century United States","volume":"42","author":"Cutler","year":"2005","journal-title":"Demography"},{"key":"2020073002271401600_CIT0002","doi-asserted-by":"crossref","first-page":"e0005376","DOI":"10.1371\/journal.pntd.0005376","article-title":"The burden of typhoid fever in low- and middle-income countries: a meta-regression approach","volume":"11","author":"Antill\u00f3n","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"2020073002271401600_CIT0003","doi-asserted-by":"crossref","first-page":"e0008048","DOI":"10.1371\/journal.pntd.0008048","article-title":"Changes in historical typhoid transmission across 16 U.S. cities, 1889\u20131931: quantifying the impact of investments in water and sewer infrastructures","volume":"14","author":"Phillips","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"2020073002271401600_CIT0004","doi-asserted-by":"crossref","first-page":"e570","DOI":"10.1016\/S2214-109X(14)70301-8","article-title":"Burden of typhoid fever in low-income and middle-income countries: a systematic, literature-based update with risk-factor adjustment","volume":"2","author":"Mogasale","year":"2014","journal-title":"Lancet Glob Health"},{"key":"2020073002271401600_CIT0005","first-page":"346","article-title":"The global burden of typhoid fever","volume":"82","author":"Crump","year":"2004","journal-title":"Bull World Health"},{"key":"2020073002271401600_CIT0006","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"390","author":"GBD 2017 Causes of Death Collaborators","year":"2017","journal-title":"Lancet"},{"key":"2020073002271401600_CIT0007","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.vaccine.2018.04.022","article-title":"Typhoid vaccines: WHO position paper, March 2018\u2014recommendations","volume":"37","author":"World Health Organization","year":"2019","journal-title":"Vaccine"},{"key":"2020073002271401600_CIT0008","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/cid\/ciy190","article-title":"Case fatality rate of enteric fever in endemic countries: a systematic review and meta-analysis","volume":"67","author":"Pieters","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2020073002271401600_CIT0009","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1136\/bmj.316.7125.110","article-title":"Typhoid fever vaccines: a meta-analysis of studies on efficacy and toxicity","volume":"316","author":"Engels","year":"1998","journal-title":"BMJ"},{"key":"2020073002271401600_CIT0010","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1056\/NEJM200104263441701","article-title":"The efficacy of a Salmonella Typhi Vi conjugate vaccine in two-to-five-year-old children","volume":"344","author":"Lin","year":"2001","journal-title":"N Engl J Med"},{"key":"2020073002271401600_CIT0011","article-title":"Millions of children set to be protected against typhoid fever","author":"Gavi, the Vaccine Alliance","year":"2017"},{"key":"2020073002271401600_CIT0012","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1016\/S0140-6736(17)32149-9","article-title":"Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial","volume":"390","author":"Jin","year":"2017","journal-title":"Lancet"},{"key":"2020073002271401600_CIT0013","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/cid\/civ295","article-title":"Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study","volume":"61","author":"Mohan","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2020073002271401600_CIT0014","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/cid\/ciy878","article-title":"Introduction of typhoid conjugate vaccines in Africa and Asia","volume":"68","author":"Neuzil","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2020073002271401600_CIT0015","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/cid\/ciy1115","article-title":"The time is now to control typhoid","volume":"68","author":"Pollard","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2020073002271401600_CIT0016","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/cid\/ciy1104","article-title":"A phase II, randomized, double-blind, controlled safety and immunogenicity trial of typhoid conjugate vaccine in children under 2 years of age in Ouagadougou, Burkina Faso: a methods paper","volume":"68","author":"Laurens","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2020073002271401600_CIT0017","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/cid\/ciy1103","article-title":"Typhoid Vaccine Acceleration Consortium Malawi: a phase III, randomized, double-blind, controlled trial of the clinical efficacy of typhoid conjugate vaccine among children in Blantyre, Malawi","volume":"68","author":"Meiring","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2020073002271401600_CIT0018","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/cid\/ciy1107","article-title":"Assessing the Impact of a Vi-polysaccharide conjugate vaccine in preventing typhoid infection among Bangladeshi children: a protocol for a phase IIIb trial","volume":"68","author":"Theiss-Nyland","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2020073002271401600_CIT0019","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/cid\/ciy1106","article-title":"Assessing the impact of a Vi-polysaccharide conjugate vaccine in preventing typhoid infections among Nepalese children: a protocol for a phase III, randomized control trial","volume":"68","author":"Theiss-Nyland","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2020073002271401600_CIT0020","first-page":"S2","article-title":"Global Advisory Committee on Vaccine Safety, 5\u20136 December 2018","volume":"94","author":"World Health Organization","year":"2019","journal-title":"Wkly Epidemiol Rec"},{"key":"2020073002271401600_CIT0021","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1905047","article-title":"Phase 3 efficacy analysis of a typhoid conjugate vaccine trial in Nepal","volume":"381","author":"Shakya","year":"2019","journal-title":"N Engl J Med"},{"key":"2020073002271401600_CIT0022","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1905047","article-title":"Phase 3 efficacy analysis of a typhoid conjugate vaccine trial in Nepal","volume":"381","author":"Shakya","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/71\/Supplement_2\/S155\/33546454\/ciaa370.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/71\/Supplement_2\/S155\/33546454\/ciaa370.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T06:27:40Z","timestamp":1596090460000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/71\/Supplement_2\/S155\/5877827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,29]]},"references-count":22,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2020,7,29]]},"published-print":{"date-parts":[[2020,7,29]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa370","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,8,15]]},"published":{"date-parts":[[2020,7,29]]}}}